NQO1-Mediated tumor-selective lethality and radiosensitization for head and neck cancer

Molecular Cancer Therapeutics

Volumn 15, Issue 7, 2016, Pages 1757-1767

  Li, Long Shan ^a,b   Reddy, Srilakshmi ^a,b   Lin, Zhen Hua ^c   Liu, Shuangping ^c   Park, Hyunsil ^a,b   Chun, Stephen G ^d   Bornmann, William G ^d   Thibodeaux, Joel ^b   Yan, Jingsheng ^b   Chakrabarti, Gaurab ^a,b   Xie, Xian Jin ^b   Sumer, Baran D ^b   Boothman, David A ^a,b   Yordy, John S ^a,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c YANBIAN UNIVERSITY MEDICAL COLLEGE   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Valley Radiation Therapy Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LAPACHONE; DNA; OXIDOREDUCTASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; BETA-LAPACHONE; CATALASE; NAPHTHOQUINONE; NQO1 PROTEIN, HUMAN; RADIOSENSITIZING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; LONG TERM SURVIVAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TUMOR XENOGRAFT; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK NEOPLASMS; IONIZING RADIATION; METABOLISM; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CATALASE; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; RADIATION TOLERANCE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979282977     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0765     Document Type: Article

References (30)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Salama JK, Vokes EE. Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol 2008;35:251-61.
3. Bhide SA, Nutting CM. Recent advances in radiotherapy. BMC Med 2010; 8:25.
4. Marin A, Lopez de Cerain A, Hamilton E, Lewis AD, Martinez-Penuela JM, Idoate MA, et al. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer 1997;76:923-9.
5. Ough M, Lewis A, Bey EA, GaoJ, Ritchie JM, Bornmann W, etal. Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biol Ther 2005;4:95-102.
6. Dong Y, Bey EA, Li LS, Kabbani W, Yan J, Xie XJ, et al. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer Res 2010;70:8088-96.
7. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, et al. An NQO1-and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A 2007;104:11832-7.
8. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 2000;275:5416-24.
9. Tagliarino C, Pink JJ, Reinicke KE, Simmers SM, Wuerzberger-Davis SM, Boothman DA. Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biol Ther 2003;2:141-52.
10. Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J Biol Chem 2001;276:19150-9.
11. Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, et al. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of betalapachone for pancreatic cancer therapy. Clin Cancer Res 2011;17:275-85.
12. Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res 2012;72:3038-47.
13. Boothman DA, Greer S, Pardee AB. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res 1987;47:5361-6.
14. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Res 1989;49:605-12.
15. Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calciumdependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem 2006;281:33684-96.
16. Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, et al. Catalase abrogates beta-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Mol Cancer Ther 2013;12:2110-20.
17. Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, et al. Betalapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res 2010;70:3896-904.
18. Nasongkla N, Wiedmann AF, Bruening A, Beman M, Ray D, Bornmann WG, et al. Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. Pharm Res 2003;20:1626-33.
19. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011;17:7248-64.
20. Li LS, Morales JC, Hwang A, Wagner MW, Boothman DA. DNA mismatch repair-dependent activation of c-Abl/p73alpha/GADD45alpha-mediated apoptosis. J Biol Chem 2008;283:21394-403.
21. Wagner MW, Li LS, Morales JC, Galindo CL, Garner HR, Bornmann WG, et al. Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses. J Biol Chem 2008;283:21382-93.
22. Ma Y, Kong J, Yan G, Ren X, Jin D, Jin T, et al. NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer 2014;14:414.
23. Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S, et al. Non-smallcell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006;66:9601-8.
24. Lee JJ, Kong M, Ayers GD, Lotan R. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 2007;17:461-80.
25. Gerber DE, Arriaga Y, Beg MS, Dowell JE, Schiller JH, Frankel A, et al. A Phase 1 correlative study of ARQ761, a b-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosis. Eur J Cancer 2014;50:84-5.
26. Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, et al. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxid Redox Signal 2014;21:237-50.
27. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
28. Goodwin PM, Lewis PJ, Davies MI, Skidmore CJ, Shall S. The effect of gamma radiation and neocarzinostatin on NAD and ATP levels in mouse leukaemia cells. Biochim Biophys Acta 1978;543:576-82.
29. Yamamori T, Meike S, Nagane M, Yasui H, Inanami O. ER stress suppresses DNA double-strand break repair and sensitizes tumor cells to ionizing radiation by stimulating proteasomal degradation of Rad51. FEBS Lett 2013;587:3348-53.
30. Lee H, Park MT, Choi BH, Oh ET, Song MJ, Lee J, et al. Endoplasmic reticulum stress-induced JNK activation is a critical event leading to mitochondria-mediated cell death caused by beta-lapachone treatment. PLoS One 2011;6:e21533.